Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
152 hedge funds and large institutions have $426M invested in Progenics Pharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 66 increasing their positions, 43 reducing their positions, and 24 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 43
4% less funds holding
Funds holding: 159 → 152 (-7)
18% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $2.03M
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
30% less capital invested
Capital invested by funds: $612M → $426M (-$186M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$9.98M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.19M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.13M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.21M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$11.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.2M |
| 3 |
BC
Broadfin Capital
New York
|
-$7.37M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.36M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$4.3M |
PGNX Hedge Fund Activity: Q2 2017 in Review
152 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2017, worth a combined $426M — down 30% from $612M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PGNX and 17 opened new positions — a net loss of 7 holders — while 43 trimmed existing stakes and 66 added.
The largest buyer was Eagle Asset Management, adding an estimated $9.98M. The largest seller was Park West Asset Management, cutting an estimated $11.7M.
- 152 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2017, down from 159 in Q1 2017.
- Funds reported $426M of Progenics Pharmaceuticals Inc stock for Q2 2017, down 30% quarter-over-quarter.
- 17 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2017 and 24 closed out, a net change of -7 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q2 2017 was Eagle Asset Management, an estimated $9.98M added.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2017 was Park West Asset Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2017.